Medline Industries Recalls Reprocessed ViewFlex Xtra ICE Catheters Due to Potential Particle Contamination
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Medline Industries, LP has issued a Class I recall for 650 reprocessed ViewFlex Xtra ICE Catheters that may contain residual material, posing risks of infection or embolism.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on February 25, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — FDA Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, MedicalDevices) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
Medline Industries, LP has initiated a voluntary Class I recall of specific lots of reprocessed ViewFlex Xtra ICE Catheters. The recall was triggered because these reprocessed devices may contain small particles of residual material. If these affected devices are used during medical procedures, there is a significant risk of an inflammatory response, systemic infection, or granulomatous reaction. Furthermore, the presence of these particles could cause a thrombus reaction, potentially leading to life-threatening conditions such as cerebral or pulmonary embolism, or deep vein thrombosis.
Which Products Are Affected
The recall affects 650 units distributed nationwide across the United States. The specific products involved are:
- Product Name: Medline ReNewal Reprocessed ViewFlex Xtra ICE Catheters
- Model: ViewFlex Xtra ICE Catheter 9F x 90cm (D087031RH)
- UDI-DI (Case): 20197344019554
- UDI-DI (Each): 10197344019557
- Affected Lot Numbers: EP250324, EP250416, EP250512, EP250521, EP250609, EP250630, EP250710, and EP250724.
- Recall Number: Z-1323-2026
What You Should Do
Medline Industries, LP notified affected customers via a formal letter initiated on December 22, 2025. Healthcare facilities and providers should immediately check their inventory for the specific lot numbers listed above. Any affected products should be quarantined and handled according to the instructions provided in the firm's notification letter. For further information regarding returns or specific guidance, facilities should contact Medline Industries, LP directly.
Why This Matters
This is a Class I recall, the most serious category, indicating that the use of the affected product could cause serious health consequences or death. The potential for residual material to enter the bloodstream poses a direct risk of embolism or severe systemic infection.
Source
Information provided by the FDA.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.
What is this FDA recall about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more FDA Recalls updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category